LISTING OF THE CLAIMS

1. (Cancelled).		
2. (Cancelled).		
3. (Cancelled).		
4. (Cancelled).		
5. (Cancelled).		
6. (Cancelled).		
7. (Cancelled).		
8. (Cancelled).		
9. (Cancelled).		
10. (Cancelled).		
11. (Cancelled).		
12. (Cancelled).		
13. (Cancelled).		
14. (Cancelled).		
15. (Cancelled).		
16. (Cancelled).		
17. (Cancelled).		

	Electronically filed August 16, 200
18. (Cancelled).	
19. (Cancelled).	
20. (Cancelled).	

23. (New). A pharmaceutical composition comprising:

(Cancelled).
(Cancelled).

- fenofibric acid or a salt thereof; and at least one binder.
- (New). The pharmaceutical composition of claim 23, wherein the composition further comprises a coating.
 - 25. (New). The pharmaceutical composition of claim 23, wherein the binder is an enteric binder.
- 26. (New). The pharmaceutical composition of claim 25, wherein the enteric binder is an enteric polymer.
- 27. (New). The pharmaceutical composition of claim 26, wherein the enteric polymer is selected from the group consisting of hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetate succinate, carboxymethylcthylcellulose, cellulose acetate phthalate, cellulose acetate trimellitate and carboxymethylcellulose sodium.
- 28. (New). The pharmaceutical composition of claim 27, wherein the enteric polymer is selected from copolymers based on (meth)acrylic acid and at least one alkyl (meth)acrylic acid ester.
- (New). The pharmaceutical composition of claim 28, wherein the alkyl (meth)acrylic acid ester is methyl methacrylate.
- 30. (New). The pharmaceutical composition of claim 29, wherein the copolymers have a ratio of free carboxyl groups to esterified carboxyl groups of 2:1 to 1:3.

- 31. (New). The pharmaceutical composition of claim 30, wherein the ratio is 1:1.
- 32. (New). The pharmaceutical composition of claim 23, wherein the fenofibric acid or salt thereof comprises 5 to 60% by weight of the composition.
- 33. (New). The pharmaceutical composition of claim 23, wherein the binder is a non-enteric binder.
- 34. (New). The pharmaceutical composition of claim 33, wherein the non-enteric binder is selected from the group consisting of: a synthetic polymer, a modified natural polymer, a natural polymer and a nonpolymeric binder.
 - 35. (New). The pharmaceutical composition of claim 23, wherein the composition is a tablet.
 - 36. (New). The pharmaceutical composition of claim 23, wherein the composition is a capsule.
- (New). A method for oral administration of fenofibric acid or salt thereof, comprising administering the pharmaceutical composition of claim 23.